Metabolic Dysfunction and Resmetirom

The introduction outlines metabolic dysfunction and resmetirom's significance in treating MASH and liver fibrosis. Clinical trials demonstrate resmetirom's efficacy and improvement in NASH patients. Availability in the US is expected in April, with limited distribution. Resmetirom's impact on medical specialties offers educational opportunities and integration perspectives. The conclusion emphasizes resmetirom's significance and future developments in metabolic dysfunction treatment, includi...